| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6713086 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
| US6528091 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
| US6720004 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
| US6511678 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
| US6528090 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
| US6419953 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
|
US6528090 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
|
US6511678 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
|
US6419953 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
|
US6720004 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
|
US6713086 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
|
US6528091 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
Depakote Er is owned by Abbvie.
Depakote Er contains Divalproex Sodium.
Depakote Er has a total of 12 drug patents out of which 12 drug patents have expired.
Expired drug patents of Depakote Er are:
- US6713086
- US6528091
- US6720004
- US6511678
- US6528090
- US6419953
- US6528090*PED
- US6511678*PED
- US6419953*PED
- US6720004*PED
- US6713086*PED
- US6528091*PED
Depakote Er was authorised for market use on 31 May, 2002.
Depakote Er is available in tablet, extended release;oral dosage forms.
Depakote Er can be used as treatment of epilepsy and/or migraine., treatment of epilepsy.
The generics of Depakote Er are possible to be released after 18 June, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Sep 24, 2011 |
Drugs and Companies using DIVALPROEX SODIUM ingredient
Market Authorisation Date: 31 May, 2002
Treatment: Treatment of epilepsy and/or migraine.; Treatment of epilepsy
Dosage: TABLET, EXTENDED RELEASE;ORAL
DEPAKOTE ER family patents
